Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG010 plus sorafenib in advanced or metastatic solid tumors after prior treatment failure
ACTRN12620000849998Phase 2Recruiting
- Sponsor
- Metagone Biotech
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of MG010 and sorafenib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 2 more (4 arms), sponsored by Metagone Biotech. Primary endpoints: Pharmacokinetic composite outcome measures, Safety outcome measures and 1 more. Started May 2020; status: recruiting.
02
Drugs
MG010sorafenib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ACTRN12620000849998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000849998.